Downloading...
Download

Gileadscience

Gilead Sciences (GILD): Pattern Still Intact—What’s the Plan?Let’s quickly review our open position in $GILD. We’ve managed to turn the whole chart around, and I hope everyone who bought in had the strength to sit it out. It was a close call with the stop loss, but now we’re up significantly, and we’ve moved our stop loss closer to $65.46. So far, we’re up 17%, and we don’t want to dictate when to take profits. If you’re in, do your own research and take profits whenever you feel comfortable—it's all up to you 👍. If you take a closer look, you’ll see that NASDAQ:GILD has been following a nice upward pattern: a surge, then three candles down, then another surge. I’m not sure how long this pattern will hold, but as long as we don’t retrace too much, we should be fine. I also like that we’re respecting all the key levels. The RSI is about to be overbought, so we might see another three candles down, but this time it could be a deeper pullback. We’ll see how it plays out, but we’re very pleased with this swing trade so far. Congratulations to everyone who’s been riding this wave 🍾.
NASDAQ:GILDLong
by freeguy_by_wmc
2
Gilead Sciences (GILD): First Take Profit in a High RangeGilead Sciences is now back trading at the high end of its range, and we’ve decided to take our first profit here. It’s crucial to respect range-bound trading, and there is a strong possibility of a pullback at this point. However, we don’t expect this pullback to reach the lower end of the range again but rather settle in the middle. If NASDAQ:GILD reclaims this range high, it could provide even more upside and new opportunities. We are also raising our stop loss to $65.80 to lock in gains. Gilead serves as our "natural hedge" against broader risk-on market conditions, and with a 40% bounce from the range low at the same time the S&P 500 is hitting new all-time highs, it’s clear that Gilead can benefit as well. We’re keeping a close eye on this stock, and if another opportunity arises, we’ll be ready to act.
NASDAQ:GILDLong
by freeguy_by_wmc
Gilead's Trodelvy Faces Setback in Lung Cancer Trial In a recent announcement, Gilead Sciences ( NASDAQ:GILD ) disclosed disappointing results from a late-stage trial evaluating its antibody-drug conjugate, Trodelvy, in second-line treatment for advanced non-small cell lung cancer (NSCLC). The Phase 3 study, aiming to expand Trodelvy's applications, did not meet its primary goal of significantly improving survival for previously treated patients. Despite a noted three-month survival benefit for a subgroup, the overall outcome fell short of statistical significance. This setback raises questions about Trodelvy's potential in lung cancer and underscores the challenges in developing effective treatments for this complex disease. The Trial and Its Implications: The trial involved 603 patients with metastatic or advanced NSCLC who had experienced disease progression despite standard platinum-based chemotherapy and checkpoint inhibitor treatment. Gilead reported that patients receiving Trodelvy exhibited longer survival compared to those on chemotherapy, but the difference did not reach statistical significance. Notably, a subgroup of patients who did not respond to their last checkpoint inhibitor treatment showed a more than three-month survival benefit. Gilead plans to discuss these results with regulators and present the full data at an upcoming medical meeting, indicating a commitment to transparent communication and a thorough examination of the findings. Exploring Trodelvy's Potential: Despite the setback, Gilead ( NASDAQ:GILD ) remains optimistic about Trodelvy's potential in metastatic NSCLC. The company emphasizes the drug's positive impact on a specific patient subgroup and expresses confidence in Trodelvy's broader lung cancer clinical development program. Gilead's Chief Medical Officer, Merdad Parsey, highlights ongoing Phase 2 and 3 trials investigating Trodelvy in combination with Keytruda as an initial treatment for NSCLC patients. The company's dedication to understanding the drug's effects and exploring potential pathways reflects a commitment to advancing cancer care. Trodelvy's Safety Profile and Current Approvals: Gilead ( NASDAQ:GILD ) reassures stakeholders by affirming that Trodelvy's safety profile aligns with prior studies, with common adverse events being neutropenia (low white blood cell counts) and diarrhea. It's worth noting that Trodelvy is already approved by U.S. regulators for specific advanced breast cancer and bladder cancer indications. In the first nine months of the previous year, Gilead reported sales of $765 million for Trodelvy, attesting to its commercial success in the approved indications. Future Prospects and Challenges: Despite the setback in the second-line lung cancer trial, Gilead remains resilient in its pursuit of innovative solutions for oncology. The ongoing front-line Phase 3 trial combining Trodelvy with Keytruda suggests a strategic focus on exploring novel treatment approaches. However, as emphasized by Parsey, results from this trial are not expected for at least a couple of years, highlighting the prolonged timeline inherent in clinical research. Conclusion: Gilead's ( NASDAQ:GILD ) recent trial results for Trodelvy in second-line NSCLC treatment present a nuanced narrative of challenges and opportunities in the evolving landscape of cancer therapeutics. The company's commitment to transparency, ongoing research, and exploration of combination therapies underscores the complexity of addressing lung cancer, one of the most formidable challenges in oncology. As the full dataset becomes available and discussions with regulators unfold, stakeholders will eagerly anticipate the next chapter in Trodelvy's journey, hoping for breakthroughs that could reshape the future of lung cancer treatment.
NASDAQ:GILD
by DEXWireNews
Arcellx Inc (ACLX) Partners With Gilead Gilead Sciences is devoting another $200 million to its existing partnership with Arcellx the biotechnology companies said Wednesday. Kite, a Gilead (ticker: GILD) company, has exercised an option to negotiate a license for Arcellx ‘s ARC-SparX program, ACLX-001, in multiple myeloma. The companies said they also expanded the scope of their collaboration for Arcellx’s CART-ddBCMA to include lymphomas. Arcellx Inc (ACLX) stock has risen 164.62% over the last 12 months. Arcellx Inc (ACLX) stock is higher by 6.82% while the S&P 500 has risen 0.03% as of 12:43 PM on Thursday, Nov 16. ACLX has risen $3.41 from the previous closing price of $49.99 on volume of 440,137 shares. Over the past year the S&P 500 has risen 13.78% while ACLX has risen 164.62%. ACLX lost -$2.78 per share in the over the last 12 months. Arcellx Inc (ACLX) Company Description Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Price Momentum ACLX is trading near the top of its 52-week range and above its 200-day simple moving average. What does this mean? Investors have been pushing the share price higher, and the stock still appears to have upward momentum. This is a positive sign for the stock's future value.
NASDAQ:ACLX
by DEXWireNews
1
GILD Gilead upside potentialReuters Adage Capital Partners GP LLC Dissolves Share Stake In Moderna, Takes In Gilead Sciences! Reuters: Germany requests 5% of EU supply of remdesivir Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the antiviral drug's effectiveness in treating COVID-19. A course of treatment for COVID-19 requires six doses and costs 2,070 euros ($2,407) per treatment, under the terms of the deal. The indicators are showing buy signals on every timeframe! If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:GILDLong
by TopgOptions
2
ridethepig | Gilead to ATH's with Remdesivir📍 The effect of Remdesivir... The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in. Compare the following two diagrams: Phase III trials & Chinese red carpet Buyers maintaining a strong floor. In the first, you will notice how once we got the break of the channel buyers were allowed to go wandering all the way to the target on grounds of safety! The second wave looks inevitable despite the political fairydust around re-openings, stimulus is running out and now the attempt to reinstate pockets of further lockdowns will make activity immovable. Thus the question, why adding more Gilead? When building a long/short portfolio, we must add hedges and blocks accordingly. The strategic protection with Gilead is pragmatic, 450 million new customers unlocked via European clearance & we already got the ✅ for the red carpet from China. Complacency around the virus is remarkable, UK cheerleading "Super Saturday" and US "Independence Day" ... who would have thought we are in the middle of a pandemic. In any case... An attractive constellation for a swing towards all time highs. Thanks as usual for keeping the feedback coming 👍 or 👎
NASDAQ:GILDLong
by ridethepig
7
Can the New FDA Nod of Approval Push Gilead to New Highs U.S. FDA approved Gilead Sciences Inc.’s experimental antiviral drug, remdesivir, for use as it’s showing good signs of helping hospitalised patients recover more quickly from Corona Virus. From a Trend Analysis perspective - price action has been very choppy with lots of buying and selling in an almost Up-trending consolidation. We expect Gilead to push higher with this recent news coupled with it Beating Earning Expectations for Q1 2020. This stock isnt a value stock with a PE of 18x and a Price to Book of 4x but it isn't overly expensive considering its growth potential (PEG 5yr 0.57).
NASDAQ:GILDLong
by Tuhi_Capital
GILEAD Short Term Uptrend Trade PlanTrade Plan for Gilead Sciences. Will look to enter at bottom of uptrend channel (75.3) , Stop Loss once uptrend broken (74). Target Price at 86. Potential Price at 96. Personally will take profit at resistances as insurance. Upside for Gilead: 1a) Possible treatment for Covid-19 (Remdesivir) 1b) Possible 2nd wave of virus 2) Possible FDA approval of Arthritis drug Downside for Gilead: 1) Leaked report of Remdesivir failing in China randomized trial, which was cancelled early due to low enrollment numbers. Bears clinging on hopes that the conclusion was inaccurate due to short duration of study
NASDAQ:GILDLong
by DicksonChong
1